The European Commission has revised its preliminary position that the CBD should be treated as a narcotic, which will allow the development of product commercialization at the CBD!
The Commission on Wednesday sent a statement to the European Industrial Hemp Association and at least one other applicant for product authorisation to the CBD, stating that the cannabidiol derived from hemp should not be regulated as a narcotic and can therefore be considered a food.
This decision is a relief for the European hemp industry as it reassures processors and manufacturers that their edible products containing CBD will not be banned from the European market.
CBD was included in the Novel Food category by the EU in January 2019, and since then has undergone extensive testing and authorisation by food authorities before it can be authorised in products and marketed as food in all 27 EU Member States. The European Commission, the executive arm of the European Union, said in July that it had stopped reviewing applications for pre-marketing authorisation of products in the CBD as it decided whether the CBD should be regulated as a narcotic.
The Commission cited last month's Court of Justice ruling that CBD derived from the whole hemp plant is not a narcotic under an international drugs treaty and is therefore subject to EU legislation on the free movement of goods between Member States.
The Commission's full statement to applicants for novel food authorisation reads as follows:
"In the light of the comments received from the applicants and the recent Court ruling in Case C-663/184, the Commission has reviewed its preliminary assessment and concludes that cannabidiol should not be considered a drug within the meaning of the 1961 UN Single Convention on Narcotic Drugs as it does not have a psychotropic effect. Consequently, cannabidiol can be qualified as a food, provided that the other conditions of Article 2 of Regulation (EC) No 178/2002 are also fulfilled".
Kanabiz welcomes this decision, which is a step in the right direction for consumers, as it should give them access to many more products for their health.